Trametinib

CAS 871700-17-3 3 API suppliersSmall Molecule

Overview

Trametinib is a kinase inhibitor used for the treatment of melanoma, specifically targeting MEK1 and MEK2. It is often used in combination with other medications to treat unresectable or metastatic melanoma with a mutation in the BRAF gene.

API suppliers (3)

Suppliers of Trametinib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

Where these suppliers are
India2China1

3 of 3 hold a GMP certificate on record in the EU or UK registers

Therapeutic areas

OncologyMelanoma
Verified Supplier Partner

Do you supply Trametinib? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.